Amicus Therapeutics (FOLD): Revenue Loss from migalastat Drives PT Cut - Baird
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Baird analyst, Michael Ulz, reiterated his Neutral rating on shares of Amicus Therapeutics (NASDAQ: FOLD) and cut his price target to $7 from $9 after the company provided a disappointing update on the regulatory path forward for migalastat in the US. The company now requires an additional gastrointestinal (GI) study, delaying timelines.
Expectations embed existing data supporting an accelerated approval (Galafold approved in Europe). While the GI data is not expected until 2019 and could lead to full approval but in the interim he is removing US migalastat revenues from the model.
No change to the Neutral rating, but expect shares to be under pressure.
Shares of Amicus Therapeutics closed at $8.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MKM Partners Raises Price Target on Finisar (FNSR) to $43 Following 2Q
- Jefferies Adjusts Estimates on Ciena (CIEN) - PT to $29
- BMO Capital Raises Price Target on Dollar Tree (DLTR) to $96; Reiterates Market Perform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!